

Title: Gut Matters: Revealing the Connection between the Gut and Cardiovascular Health

Robert G. Silverman, DC, MS, DABCN, DCBCN, CNS, CCN, CSCS, CIISN, CKTP, CES, HKC, FAKTR

Description:

When the gut microbiome is out of balance or inflamed, the impact is felt throughout the body, including the cardiovascular system. If the gut is healthy and functioning properly, microbial metabolites—such as lipopolysaccharide (LPS)—and other antigens are appropriately contained within the gut lumen. However, a dysfunctional, permeable intestinal barrier allows microbial antigens and metabolites to be translocated from the gut into the bloodstream. Once intestinal permeability allows LPS and antigens to escape into circulation, they can trigger immune-response inflammation that contributes to insulin resistance, hypertension, atherosclerosis, coronary artery disease, atrial fibrillation, and cardiomyopathy.

In this incisive new presentation, Dr. Robert Silverman leads you through the intricate interplay between gut microbiota composition, gut permeability, immune-inflammatory responses, metabolic pathways, and their collective influence on cardiovascular well-being. You'll come away with a thorough understanding of new functional medicine strategies for improved GI system function and how they can help reduce cardiovascular risk and lead to optimal health.

Dr. Silverman explores the cutting-edge research defining the gut microbiota's pivotal role in maintaining and damaging cardiovascular health. The exciting realm of therapeutic interventions that target the gut microbiota to optimize cardiovascular outcomes will also be discussed. From probiotics and prebiotics to personalized dietary and lifestyle modifications, these innovative strategies offer promising avenues for manipulating the gut microbiota composition and functionality.

This presentation will review clinical assessments for evaluating the integrity of the intestinal barriers and testing to determine the presence of systemic bacterial toxins and predictive antibodies for cardiovascular disease. Detailed clinical approaches and treatment protocols for restoring damaged barriers and eliminating gut dysbiosis will also be discussed.

Learning Objectives:

By the end of this presentation, the attendees will be able to:

1. Elucidate the effect of intestinal barrier dysfunction on the cardiovascular system and its role in the pathogenesis of cardiovascular disease.
2. Apply advanced diagnostic laboratory testing and blood chemistry analysis to assess intestinal dysfunctions.
3. Utilize optimal lifestyle adaptations in diet, exercise, and supplement protocols, including protocols for gut healing, to help prevent cardiovascular disease and improve quality of life.

References:

- 1) Rebecca CC, Caroline LH, Kate S. *Cell Research*, Oct. 3, 2018
- 2) Forsyth et al. Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson's disease. *PLoS ONE*, 2011; 6(12): e28032
- 3) Lee et al. Neuro-inflammation induced by lipopolysaccharide causes cognitive impairment through enhancement of beta-amyloid generation. *J Neuroinflammation*, 2008; 5:37
- 4) Candelli M, Franza L, Pignataro G, et al. Interaction between Lipopolysaccharide and Gut Microbiota in Inflammatory Bowel Diseases. *Int J Mol Sci*. 2021 Jun 10;22(12):6242
- 5) Gut Microbiota, Lipopolysaccharides, and Innate Immunity in the Pathogenesis of Obesity and Cardiovascular Risk, *Endocrine Reviews*, 1 Dec 2010;3(6):817–844
- 6) Ohlsson B, Orho-Melander M, Nilsson PM. Higher Levels of Serum Zonulin May Rather Be Associated with Increased Risk of Obesity and Hyperlipidemia, Than with Gastrointestinal Symptoms or Disease Manifestations. *Int J Mol Sci*. 2017 Mar 8;18(3):582
- 7) M Witkowski, TL Weeks, SL Hazen. Gut Microbiota and Cardiovascular Disease. *Circulation Research*, 2020;127:553–570
- 8) MM Rahman, F Islam, M Harun, et al. The Gut Microbiota (Microbiome) in Cardiovascular Disease and Its Therapeutic Regulation. *Frontiers in Cellular and Infection Microbiology*, 20 June 2022;12:903570
- 9) Sharifi-Rad J, Rodrigues CF, Sharopov F, et al. Diet, Lifestyle and Cardiovascular Diseases: Linking Pathophysiology to Cardioprotective Effects of Natural Bioactive Compounds. *Int J Environ Res Public Health*. 2020 Mar 30;17(7):2326
- 10) Sunkara A, Raizner A. Supplemental Vitamins and Minerals for Cardiovascular Disease Prevention and Treatment. *Methodist Debaque Cardiovasc J*. 2019 Jul-Sep;15(3):179-184
- 11) Lewis CV, Taylor WR. Intestinal barrier dysfunction as a therapeutic target for cardiovascular disease. *Am J Physiol Heart Circ Physiol*. 2020 Dec 1;319(6):H1227-H1233
- 12) F Violi, V Cammisotto, S Bartimoccia, et al. Gut-derived low-grade endotoxaemia, atherothrombosis and cardiovascular disease. *Nat Rev Cardiol*, 15 July 2022;20:24–37